Q-omics provides the consensus-scored NAA25 profile across patient tissues and cancer cell-line models. NAA25 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NAA25 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, NAA25 protein abundance shows 27,820 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where NAA25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAA25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAA25 survival associations across molecular data types. NAA25 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAA25 RNA expression–survival associations across cancer types. High NAA25 expression shows unfavorable associations in MESO, KIRP, ACC, LIHC and KIRC, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NAA25 RNA expression.
This table summarizes NAA25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAA25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAA25 shows higher tumor expression in HNSC, KIRP, KIRC, BLCA, STAD and COAD. The HNSC box plot shows higher NAA25 RNA expression in tumor versus normal tissue (log2 FC = +0.682, t-test p < 0.001).
This table shows molecular features associated with NAA25 in patient tissues and cancer cell lines. In patient samples, NAA25 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NAA25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
